Investment in Vivosense Software to Promote Wearable Sensor Data in Clinical Trials

April 11, 2022

The wearable sensor consulting and data analysis firm Vivosense has just announced the closing of a $25 million investment to build its software platform. Its Vivosense software helps clinical trials access and use wearable sensor data in clinical trials. The impact of the new Series A financing round is discussed in a new PharmaPhorum interview with Dudley Tabakin, CEO of Vivosense, Tanja Dowe, CEO of Debiopharm Innovation Fund, and Chris Garabedian, CEO of Xontogeny. Vivosense is designed, in part, to help cut through the noise present in most wearable sensor data.

According to Tabakin, “ECGs are a great example of this. You need the purest waveform to measure heart rate accurately, but when you’re moving around, a wrist-worn device may integrate a lot of ‘noise’ in the data. With most devices, that data is interpreted, and an estimate is made for the period where the true data cannot be read (the ‘noise’). In VivoSense software, we have the ability to find those regions and remove that period of time. In this way, you’re eliminating that variability.”